Tamoxifen versus raloxifene in the prevention of breast cancer

European Journal of Cancer

Volumn 38, Issue SUPPL. 6, 2002, Pages

  Wickerham, D L ^a  

^a NSABP Foundation Inc   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

RALOXIFENE; TAMOXIFEN;

ARTICLE; BREAST CARCINOMA; CANCER CHEMOTHERAPY; CANCER PREVENTION; CANCER RISK; CLINICAL TRIAL; CONFIDENCE INTERVAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; EUROPE; FEMALE; FOLLOW UP; HUMAN; MAJOR CLINICAL STUDY; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL;

ANTINEOPLASTIC AGENTS, HORMONAL; BREAST NEOPLASMS; ESTROGEN ANTAGONISTS; FEMALE; HUMANS; RALOXIFENE; RANDOMIZED CONTROLLED TRIALS; TAMOXIFEN; TREATMENT OUTCOME;

EID: 0036754825     PISSN: 09598049     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0959-8049(02)80017-X     Document Type: Article

References (4)

1. Fisher B., Constantino J.P., Wickerham D.L.et al. Tamoxifen for prevention of breast cancer: report of the National Surgical Adjuvant Breast and Bowel Project P-1 study. J Natl Cancer Inst. 90:1998;1371-1388.
2. Veronesi U., Maisonneuve P., Costa A.et al. Prevention of breast cancer with tamoxifen: preliminary findings from the Italian randomised trial among hysterectomised women. Lancet. 352:1998;93-97.
3. Powels T., Eeles R., Ashley S.et al. Interim analysis of the incidence of breast cancer in the Royal Marsden Hospital tamoxifen randomised chemoprevention trial. Lancet. 352:1998;98-101.
4. Cauley J.A., Norton L., Lippman M.E.et al. Continued breast cancer risk reduction in postmenopausal women treated with raloxifene: 4-year results from the MORE trial. Breast Cancer Res Treat. 65:2001;125-134.